BioGaia (OM:BIOG B) - Cours de l'action, nouvelles et analyse

BIOG B Aperçu des actions

BioGaia AB (publ), une entreprise de soins de santé, fournit des produits probiotiques dans le monde entier.

BIOG B analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	4/6
Performances passées	3/6
Santé financière	6/6
Dividendes	4/6

Récompenses

Le ratio cours/bénéfice ( 32.2 x) est inférieur à la moyenne du secteur Biotechs ( 24.3 x)

Les bénéfices devraient augmenter 21.24% par an

Analyse des risques

Le dividende de 6.44% n'est pas bien couvert par les flux de trésorerie disponibles

Ventes d'initiés importantes au cours des 3 derniers mois

BioGaia AB (publ) Concurrents

Swedish Orphan Biovitrum

OM:SOBI

SEK 117.0b

Biotage

OM:BIOT

SEK 13.1b

MedCap

OM:MCAP

SEK 8.2b

Sprint Bioscience

OM:SPRINT

SEK 121.1m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour BioGaia
Historique des cours de bourse
Prix actuel de l'action	SEK 107.20
Plus haut sur 52 semaines	SEK 136.60
Plus bas sur 52 semaines	SEK 94.75
Bêta	0.54
1Variation sur 1 mois	-4.54%
Variation sur 3 mois	-15.39%
Variation sur 1 an	6.88%
3Variation sur 3 ans	0.56%
Variation sur 5 ans	41.99%
Évolution depuis l'introduction en bourse	1,256.97%

Nouvelles et mises à jour récentes

BioGaia's (STO:BIOG B) Soft Earnings Don't Show The Whole Picture

Oct 29

Recent updates

BioGaia's (STO:BIOG B) Soft Earnings Don't Show The Whole Picture

Oct 29

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

Apr 25

BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 09

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

Mar 26

BioGaia (STO:BIOG B) Will Pay A Larger Dividend Than Last Year At SEK6.90

Mar 09

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

Feb 24

Does This Valuation Of BioGaia AB (publ) (STO:BIOG B) Imply Investors Are Overpaying?

Jul 24

Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)

Apr 02

BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 21

Need To Know: Analysts Are Much More Bullish On BioGaia AB (publ) (STO:BIOG B) Revenues

Feb 09

BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's

Feb 07

Some Shareholders May find It Hard To Increase BioGaia AB (publ)'s (STO:BIOG B) CEO Compensation This Year

Apr 29

Key Things To Consider Before Buying BioGaia AB (publ) (STO:BIOG B) For Its Dividend

Mar 25

The BioGaia (STO:BIOG B) Share Price Is Up 90% And Shareholders Are Holding On

Mar 04

CEO & President Isabelle Valerie Ducellier Just Bought 8.2% More Shares In BioGaia AB (publ) (STO:BIOG B)

Feb 11

Is BioGaia AB (publ)'s (STO:BIOG B) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 26

What Type Of Shareholders Own The Most Number of BioGaia AB (publ) (STO:BIOG B) Shares?

Jan 11

How Much Are BioGaia AB (publ) (STO:BIOG B) Insiders Taking Off The Table?

Dec 27

Rendement pour les actionnaires

	BIOG B	SE Biotechs	SE Marché
7D	10.6%	3.3%	1.0%
1Y	6.9%	35.0%	25.9%

Rendement vs Industrie: BIOG B a sous-performé le secteur Swedish Biotechs qui a rapporté 35 % au cours de l'année écoulée.

Rendement vs marché: BIOG B a sous-performé le marché Swedish qui a rapporté 25.9 % au cours de l'année écoulée.

Volatilité des prix

Is BIOG B's price volatile compared to industry and market?
BIOG B volatility
BIOG B Average Weekly Movement	3.9%
Biotechs Industry Average Movement	8.6%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.0%
10% least volatile stocks in SE Market	3.3%

Cours de l'action stable: BIOG B n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de BIOG B ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1990	222	Theresa Agnew	www.biogaia.com

BioGaia AB (publ), une entreprise de soins de santé, fournit des produits probiotiques dans le monde entier. L'entreprise exerce ses activités dans les segments Pédiatrie, Santé des adultes et Autres. Le segment Pédiatrie propose des gouttes, des solutions de réhydratation orale et des comprimés pour la santé intestinale, ainsi que des cultures utilisées comme ingrédient dans les préparations pour nourrissons.

BioGaia AB (publ) Résumé des fondamentaux

Comment les bénéfices et les revenus de BioGaia se comparent-ils à sa capitalisation boursière ?
BIOG B statistiques fondamentales
Capitalisation boursière	SEK 10.84b
Bénéfices(TTM)	SEK 336.82m
Recettes(TTM)	SEK 1.36b

32.2x

Ratio P/E

8.0x

Ratio P/S

Le site BIOG B est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
BIOG B compte de résultat (TTM)
Recettes	SEK 1.36b
Coût des recettes	SEK 358.07m
Marge brute	SEK 997.60m
Autres dépenses	SEK 660.78m
Les revenus	SEK 336.82m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

Feb 12, 2025

Résultat par action (EPS)	3.33
Marge brute	73.59%
Marge bénéficiaire nette	24.85%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de BIOG B?

Voir les performances historiques et les comparaisons

Dividendes

6.4%

Rendement actuel des dividendes

57%

Ratio de distribution

BIOG B Aperçu des actions

Récompenses

Analyse des risques

BioGaia AB (publ) Concurrents

OM:SOBI

SEK 117.0b

OM:BIOT

SEK 13.1b

OM:MCAP

SEK 8.2b

OM:SPRINT

SEK 121.1m

Historique des prix et performances

Nouvelles et mises à jour récentes

BioGaia's (STO:BIOG B) Soft Earnings Don't Show The Whole Picture

Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023)

BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025

Price target increased by 7.1% to kr150

Vice President of Marketing recently sold kr407k worth of stock

Executive VP & CFO recently sold kr11m worth of stock

Recent updates

BioGaia's (STO:BIOG B) Soft Earnings Don't Show The Whole Picture

Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023)

BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025

Price target increased by 7.1% to kr150

Vice President of Marketing recently sold kr407k worth of stock

Executive VP & CFO recently sold kr11m worth of stock

Vice President of Marketing exercised options to buy kr579k worth of stock.

Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.80 in 2Q 2023)

BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

First quarter 2024 earnings released: EPS: kr1.21 (vs kr1.15 in 1Q 2023)

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

BioGaia's (STO:BIOG B) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2023 earnings: EPS and revenues exceed analyst expectations

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

BioGaia (STO:BIOG B) Will Pay A Larger Dividend Than Last Year At SEK6.90

BioGaia (STO:BIOG B) Has Announced That It Will Be Increasing Its Dividend To SEK6.90

Price target increased by 22% to kr140

BioGaia's (STO:BIOG B) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Biogaia AB (Publ) Proposes an Extra Dividend

Here's Why We Think BioGaia (STO:BIOG B) Might Deserve Your Attention Today

BioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024

Third quarter 2023 earnings released

BioGaia AB (publ), Annual General Meeting, Apr 26, 2024

Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023

Biogaia AB (Publ) Appoints Theresa Agnew as CEO

Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)

BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in Sweden

BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023

Second quarter 2023 earnings released

BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults

Does BioGaia (STO:BIOG B) Deserve A Spot On Your Watchlist?

Less than half of directors are independent

First quarter 2023 earnings released

BioGaia AB (Publ) Approves Dividend for 2022

Upcoming dividend of kr2.90 per share at 2.8% yield

A Look At The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)

Full year 2022 earnings: EPS exceeds analyst expectations

Independent Director recently bought kr51k worth of stock

Price target increased by 9.1% to kr120

Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)

BioGaia AB (publ) Proposes Ordinary Dividend

Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?

Price target decreased to kr102

Third quarter 2022 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Do BioGaia's (STO:BIOG B) Earnings Warrant Your Attention?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Does This Valuation Of BioGaia AB (publ) (STO:BIOG B) Imply Investors Are Overpaying?

Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022

Price target increased to kr620

BioGaia AB (publ) Approves Extra Dividend

First quarter 2022 earnings: Revenues exceed analyst expectations

Upcoming dividend of kr14.92 per share

Price target increased to kr570

BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022

BioGaia AB (publ) Proposes Dividend, Payable on 13 May 2022

Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)